Citations

Clear

1575 citation(s) found for "Im, Gene".

Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice
Amador, Catalina , Wright, George W. , Weisenburger, Dennis D. , Greiner, Timothy C. , Lone, Waseem , Heavican, Tayla B., Smith, Lynette M. , Pileri, Stefano , Tabanelli, Valentina , Ott, German , Rosenwald, Andreas , Slack, Graham W. , Kim, Won Seog , Hyeh, Young, Li, Yuping , Dong, Gehong, Ondrejka, Sarah L. , Cook, James R. , Lim, Soon Thye , Ong, Choon Kiat , Chapman, Jennifer R. , Raess, Philipp W. , Blombery, Piers , Morris, Stephan W., Staudt, Louis M. , Chan, Wing C. , Iqbal, Javeed , Greiner, Timothy C , Heavican, Tayla B , Smith, Lynette , Pileri, Stefano , Tabanelli, Valentina , Ott, German , Savage, Kerry J , Kim, Won Seog , Hyeh, Young , Song, Joo Y , Ondrejka, Sarah , Cook, James R , Lim, Soon Thye , Ong, Choon Kiat , Inghirami, Giorgio , Raess, Philipp W , Gould, Clare , Jaffe, Elaine S , Vose, Julie , Chan, Wing C , Iqbal, Javeed , Amador, Catalina , Lone, Waseem G , Wright, George , Bouska, Alyssa , Feldman, Andrew L. , Savage, Kerry J. , Ko, Young Hyeh , Song, Joo Y. , Barrionuevo, Carlos , Inghirami, Giorgio , Bhagavathi, Sharathkumar , Gould, Clare , Jaffe, Elaine S. , Rimsza, Lisa M. , Vose, Julie M.

Mayo Clinic

Journal of Clinical Oncology | July 15, 2022 | Volume: 40 | Issue: 36 | Pages: 4261-4275

10.1200/jco.21.02707 | PMID 35839444 Get It

PURPOSE Peripheral T-cell lymphoma (PTCL) includes heterogeneous clinicopathologic entities with numerous diagnostic and treatment challenges. We previously defined robust transcriptomic signatures that distinguish common PTCL entities and identified two novel biologic and prognostic PTCL-not otherwise specified subtypes (PTCL-TBX21 and PTCL-GATA3). We aimed to consolidate a gene expression–based subclassification using formalin-fixed, paraffin-embedded (FFPE) tissues to improve the accuracy and precision in PTCL diagnosis. MATERIALS AND METHODS We assembled a well-characterized PTCL training cohort (n = 105) with gene expression profiling data to derive a diagnostic signature using fresh-frozen tissue on the HG-U133plus2.0 platform (Affymetrix, Inc, Santa Clara, CA) subsequently validated using matched FFPE tissues in a digital gene expression profiling platform (nCounter, NanoString Technologies, Inc, Seattle, WA). Statistical filtering approaches were applied to refine the transcriptomic signatures and then validated in another PTCL cohort (n = 140) with rigorous pathology review and ancillary assays. RESULTS In the training cohort, the refined transcriptomic classifier in FFPE tissues showed high sensitivity (> 80%), specificity (> 95%), and accuracy (> 94%) for PTCL subclassification compared with the fresh-frozen–derived diagnostic model and showed high reproducibility between three independent laboratories. In the validation cohort, the transcriptional classifier matched the pathology diagnosis rendered by three expert hematopathologists in 85% (n = 119) of the cases, showed borderline association with the molecular signatures in 6% (n = 8), and disagreed in 8% (n = 11). The classifier improved the pathology diagnosis in two cases, validated by clinical findings. Of the 11 cases with disagreements, four had a molecular classification that may provide an improvement over pathology diagnosis on the basis of overall transcriptomic and morphological features. The molecular subclassification provided a comprehensive molecular characterization of PTCL subtypes, including viral etiologic factors and translocation partners. CONCLUSION We developed a novel transcriptomic approach for PTCL subclassification that facilitates translation into clinical practice with higher precision and uniformity than conventional pathology diagnosis.
Geometric structure guided model and algorithms for complete deconvolution of gene expression data
Chen, Duan, Li, Shaoyu , Wang, Xue

Mayo Clinic

Foundations of Data Science | July 12, 2022 | Volume: 4 | Issue: 3 | Pages: 441

10.3934/fods.2022013 | PMID 38250319 Get It

<p style='text-indent:20px;'>Complete deconvolution analysis for bulk RNA-seq data is important and helpful to distinguish whether the differences of disease-associated GEPs (gene expression profiles) in tissues of patients and normal controls are due to changes in cellular composition of tissue samples, or due to GEPs changes in specific cells. One of the major techniques to perform complete deconvolution is nonnegative matrix factorization (NMF), which also has a wide-range of applications in the machine learning community. However, the NMF is a well-known strongly ill-posed problem, so a direct application of NMF to RNA-seq data will suffer severe difficulties in the interpretability of solutions. In this paper, we develop an NMF-based mathematical model and corresponding computational algorithms to improve the solution identifiability of deconvoluting bulk RNA-seq data. In our approach, we combine the biological concept of marker genes with the solvability conditions of the NMF theories, and develop a geometric structures guided optimization model. In this strategy, the geometric structure of bulk tissue data is first explored by the spectral clustering technique. Then, the identified information of marker genes is integrated as solvability constraints, while the overall correlation graph is used as manifold regularization. Both synthetic and biological data are used to validate the proposed model and algorithms, from which solution interpretability and accuracy are significantly improved.</p>
SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19
Serrano, Geidy E. , Walker, Jessica E. , Tremblay, Cécilia , Huentelman, Matthew J. , Belden, Christine M. , Goldfarb, Danielle, Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Caselli, Richard J. , Woodruff, Bryan K. , Haarer, Chadwick F., Ruhlen, Thomas, Nguyen, Steve, Schmitt, Dasan, Rapscak, Steven Z., Bime, Christian , Peters, Joseph L., Alevritis, Ellie, Arce, Richard, Glass, Michael J. , Vargas, Daisy, Sue, Lucia I., Intorcia, Anthony J., Nelson, Courtney M. , Oliver, Javon, Russell, Aryck, Suszczewicz, Katsuko E., Borja, Claryssa I., Cline, Madison P. , Hemmingsen, Spencer J, Qiji, Sanaria H., Hobgood, Holly M, Zhang, Haiyu , Solis, Daniel , Montine, Thomas J. , Berry, Gerald J. , Reiman, Eric M. , Röltgen, Katharina , Boyd, Scott D. , Zehnder, James L. , Desforges, Marc , DeTure, Michael , Beach, Thomas G. , Driver-Dunckley, Erika, Berry, Gerald J , Serrano, Geidy E , Piras, Ignazio Stefano , Shprecher, David , Atri, Alireza , Adler, Charles H. , Haarer, Chadwick F., Torres, Marı́a José , Peters, Joseph L, Mizgerd, Joseph P. , Sahoo, Malaya Kumar , Pinsky, Benjamin A. , Talbot, Pierre J. , Dickson, Dennis W.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | July 12, 2022 | Volume: 81 | Issue: 9 | Pages: 666-695

10.1093/jnen/nlac056 | PMID 35818336 Get It

Abstract Brains of 42 COVID-19 decedents and 107 non-COVID-19 controls were studied. RT-PCR screening of 16 regions from 20 COVID-19 autopsies found SARS-CoV-2 E gene viral sequences in 7 regions (2.5% of 320 samples), concentrated in 4/20 subjects (20%). Additional screening of olfactory bulb (OB), amygdala (AMY) and entorhinal area for E, N1, N2, RNA-dependent RNA polymerase, and S gene sequences detected one or more of these in OB in 8/21 subjects (38%). It is uncertain whether these RNA sequences represent viable virus. Significant histopathology was limited to 2/42 cases (4.8%), one with a large acute cerebral infarct and one with hemorrhagic encephalitis. Case-control RNAseq in OB and AMY found more than 5000 and 700 differentially expressed genes, respectively, unrelated to RT-PCR results; these involved immune response, neuronal constituents, and olfactory/taste receptor genes. Olfactory marker protein-1 reduction indicated COVID-19-related loss of OB olfactory mucosa afferents. Iba-1-immunoreactive microglia had reduced area fractions in cerebellar cortex and AMY, and cytokine arrays showed generalized downregulation in AMY and upregulation in blood serum in COVID-19 cases. Although OB is a major brain portal for SARS-CoV-2, COVID-19 brain changes are more likely due to blood-borne immune mediators and trans-synaptic gene expression changes arising from OB deafferentation.
Frequency, Penetrance, and Variable Expressivity of Dilated Cardiomyopathy–Associated Putative Pathogenic Gene Variants in UK Biobank Participants
Shah, Ravi A. , Asatryan, Babken , Dabbagh, Ghaith Sharaf , Aung, Nay , Khanji, Mohammed Y , Lopes, Luís R. , Holmes, Anthony , Muser, Daniele , Landstrom, Andrew P. , Semsarian, Christopher , Owens, Anjali , Petersen, Steffen E. , Chahal, C. Anwar A. , Investigators, on behalf of the Genotype-First Approach, Sharaf Dabbagh, Ghaith , Muser, Daniele , Landstrom, Andrew P , Lee, Aaron Mark , Arora, Pankaj , Semsarian, Christopher , Somers, Virend K. , Owens, Anjali T , Munroe, Patricia B , Petersen, Steffen E , Chahal, Choudhary Anwar A , Khanji, Mohammed Yunus , Asatryan, Babken , Aung, Nay , Shah, Ravi A , Lopes, Luis Rocha , Duijvenboden, Stefan van , Arora, Pankaj , Somers, Virend K. , Munroe, Patricia B. , Investigators, on behalf of the Genotype-First Approach

Mayo Clinic

Circulation | July 11, 2022 | Volume: 146 | Issue: 2 | Pages: 110-124

10.1161/circulationaha.121.058143 | PMID 35708014 Get It

Background: There is a paucity of data regarding the phenotype of dilated cardiomyopathy (DCM) gene variants in the general population. We aimed to determine the frequency and penetrance of DCM-associated putative pathogenic gene variants in a general adult population, with a focus on the expression of clinical and subclinical phenotype, including structural, functional, and arrhythmic disease features. Methods: UK Biobank participants who had undergone whole exome sequencing, ECG, and cardiovascular magnetic resonance imaging were selected for study. Three variant-calling strategies (1 primary and 2 secondary) were used to identify participants with putative pathogenic variants in 44 DCM genes. The observed phenotype was graded DCM (clinical or cardiovascular magnetic resonance diagnosis); early DCM features, including arrhythmia or conduction disease, isolated ventricular dilation, and hypokinetic nondilated cardiomyopathy; or phenotype-negative. Results: Among 18 665 individuals included in the study, 1463 (7.8%) possessed ≥1 putative pathogenic variant in 44 DCM genes by the main variant calling strategy. A clinical diagnosis of DCM was present in 0.34% and early DCM features in 5.7% of individuals with putative pathogenic variants. ECG and cardiovascular magnetic resonance analysis revealed evidence of subclinical DCM in an additional 1.6% and early DCM features in an additional 15.9% of individuals with putative pathogenic variants. Arrhythmias or conduction disease (15.2%) were the most common early DCM features, followed by hypokinetic nondilated cardiomyopathy (4%). The combined clinical/subclinical penetrance was ≤30% with all 3 variant filtering strategies. Clinical DCM was slightly more prevalent among participants with putative pathogenic variants in definitive/strong evidence genes as compared with those with variants in moderate/limited evidence genes. Conclusions: In the UK Biobank, ≈1 of 6 of adults with putative pathogenic variants in DCM genes exhibited early DCM features potentially associated with DCM genotype, most commonly manifesting with arrhythmias in the absence of substantial ventricular dilation or dysfunction.
Brain radiotoxicity-related 15CAcBRT gene expression signature predicts survival prognosis of glioblastoma patients
Reyes-González, Jesús, Garcia‐Ortíz, Humberto , Magraner-Pardo, Lorena , Pons, Tirso , Aguirre‐Cruz, Lucinda, Reyes-Abrahantes, Andy, Martínez‐Hernández, Angélica , Contreras-Cubas, Cecilia , Quiñones‐Hinojosa, Alfredo , Abrahantes-Pérez, María del Carmen , Abrahantes-Pérez, María Del Carmen , Barajas-Olmos, Francisco Martin , Moreno‐Jiménez, Sergio , Barrios‐Payán, Jorge , Ruiz-García, Henry , Hernández‐Pando, Rogélio , Orozco, Lorena

Mayo Clinic

Neuro-Oncology | July 8, 2022 | Volume: 25 | Issue: 2 | Pages: 303-314

10.1093/neuonc/noac171 | PMID 35802478 Get It

Abstract Background Glioblastoma is the most common and devastating primary brain cancer. Radiotherapy is standard of care; however, it is associated with brain radiation toxicity (BRT). This study used a multi-omics approach to determine whether BRT-related genes (RGs) harbor survival prognostic value and whether their encoded proteins represent novel therapeutic targets for glioblastoma. Methods RGs were identified through analysis of single-nucleotide variants associated with BRT (R-SNVs). Functional relationships between RGs were established using Protein-Protein Interaction networks. The influence of RGs and their functional groups on glioblastoma prognosis was evaluated using clinical samples from the Glioblastoma Bio-Discovery Portal database and validated using the Chinese Glioma Genome Atlas dataset. The identification of clusters of radiotoxic and putative pathogenic variants in proteins encoded by RGs was achieved by computational 3D structural analysis. Results We identified the BRT-related 15CAcBRT molecular signature with prognostic value in glioblastoma, by analysis of the COMT and APOE protein functional groups. Its external validation confirmed clinical relevance independent of age, MGMT promoter methylation status, and IDH mutation status. Interestingly, the genes IL6, APOE, and MAOB documented significant gene expression levels alteration, useful for drug repositioning. Biological networks associated with 15CAcBRT signature involved pathways relevant to cancer and neurodegenerative diseases. Analysis of 3D clusters of radiotoxic and putative pathogenic variants in proteins coded by RGs unveiled potential novel therapeutic targets in neuro-oncology. Conclusions 15CAcBRT is a BRT-related molecular signature with prognostic significance for glioblastoma patients and represents a hub for drug repositioning and development of novel therapies.
Faculty Opinions recommendation of Hypothesis: why different types of SDH gene variants cause divergent tumor phenotypes.
Maher, Jim

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 29, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.742209677.793593853 Get It

P1287: DISTINGUISHING BETWEEN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA USING THE LYMPH3CX GENE EXPRESSION PROFILING ASSAY
Robetorye, Ryan S. , Ramsower, Colleen , McKinney, C. L., Rimsza, Lisa M.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 1172-1173

10.1097/01.hs9.0000848012.06176.ae Get It

Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma
Ung, Choong Yong , Levee, Taylor M., Zhu, Shizhen , Ung, Choong Y, Yeo, Kok Siong , Zhang, Cheng , Correia, Cristina , Li, Hu

Mayo Clinic

Computational and Structural Biotechnology Journal | June 20, 2022 | Volume: 20 | Issue: No issue available | Pages: 3291-3303

10.1016/j.csbj.2022.06.024 | PMID 35832612 Get It

Folate Transport Gene Inactivation in Mice Increases Sensitivity to Colon Carcinogenesis
Callaway, Evelyn, Spiegelstein, Ofer , Salbaum, J. Michael, Kappen, Claudia , James, Jill, Bozinov, Daniel, Lupton, Joanne R., W.L., David , Finnell, Richard H. , Davidson, Laurie A. , Piedrahita, Jorge A. , Weeks, Brad R. , Chapkin, Robert S.

Mayo Clinic

Cancer Research | June 16, 2022 | Volume: 65 | Issue: 3 | Pages: 887-897

10.1158/0008-5472.887.65.3 Get It

Abstract Low dietary folate intake is associated with an increased risk for colon cancer; however, relevant genetic animal models are lacking. We therefore investigated the effect of targeted ablation of two folate transport genes, folate binding protein 1 (Folbp1) and reduced folate carrier 1 (RFC1), on folate homeostasis to elucidate the molecular mechanisms of folate action on colonocyte cell proliferation, gene expression, and colon carcinogenesis. Targeted deletion of Folbp1 (Folbp1+/− and Folbp1−/−) significantly reduced (P &lt; 0.05) colonic Folbp1 mRNA, colonic mucosa, and plasma folate concentration. In contrast, subtle changes in folate homeostasis resulted from targeted deletion of RFC1 (RFC1+/−). These animals had reduced (P &lt; 0.05) colonic RFC1 mRNA and exhibited a 2-fold reduction in the plasma S-adenosylmethionine/S-adenosylhomocysteine. Folbp1+/− and Folbp1−/− mice had larger crypts expressed as greater (P &lt; 0.05) numbers of cells per crypt column relative to Folbp1+/+ mice. Colonic cell proliferation was increased in RFC1+/− mice relative to RFC1+/+ mice. Microarray analysis of colonic mucosa showed distinct changes in gene expression specific to Folbp1 or RFC1 ablation. The effect of folate transporter gene ablation on colon carcinogenesis was evaluated 8 and 38 weeks post-azoxymethane injection in wild-type and heterozygous mice. Relative to RFC1+/+ mice, RFC1+/− mice developed increased (P &lt; 0.05) numbers of aberrant crypt foci at 8 weeks. At 38 weeks, RFC1+/− mice developed local inflammatory lesions with or without epithelial dysplasia as well as adenocarcinomas, which were larger relative to RFC1+/+ mice. In contrast, Folbp1+/− mice developed 4-fold (P &lt; 0.05) more lesions relative to Folbp1+/+ mice. In conclusion, Folbp1 and RFC1 genetically modified mice exhibit distinct changes in colonocyte phenotype and therefore have utility as models to examine the role of folate homeostasis in colon cancer development.